← Back to Search

Anticholinergic

Treadmill then Treadmill with Atropine for Catecholaminergic Polymorphic Ventricular Tachycardia

N/A
Waitlist Available
Led By Prince J Kannankeril, MD, MSCI
Research Sponsored by Vanderbilt University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

To test the hypothesis that increasing the sinus node rate with atropine treatment prior to exercise will reduce exercise-triggered ventricular ectopy compared to baseline in patients with CPVT.

Eligible Conditions
  • Catecholaminergic Polymorphic Ventricular Tachycardia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treadmill then Treadmill with AtropineExperimental Treatment2 Interventions
Patients will undergo treadmill exercise at baseline, then Patients will undergo treadmill exercise after IV atropine
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atropine
FDA approved
Exercise treadmill test
2016
N/A
~10

Find a Location

Who is running the clinical trial?

Vanderbilt UniversityLead Sponsor
710 Previous Clinical Trials
6,143,312 Total Patients Enrolled
Prince J Kannankeril, MD, MSCIPrincipal InvestigatorVanderbilt University Medical Center
2 Previous Clinical Trials
16 Total Patients Enrolled
~1 spots leftby Oct 2025